{"drugs":["E.E.S. 200","E.E.S. 400","E.E.S. Granules","Eryped","Eryped 200","Eryped 400","Erythromycin Ethylsuccinate"],"mono":{"0":{"id":"211750-s-0","title":"Generic Names","mono":"Erythromycin Ethylsuccinate"},"1":{"id":"211750-s-1","title":"Dosing and Indications","sub":[{"id":"211750-s-1-4","title":"Adult Dosing","mono":"<ul><li>usual dosage 400 mg orally every 6 hours; may titrate up to 4 g per day based on infection severity; may also give one-half total daily dose every 12 hours or one-third total daily dose every 8 hours<\/li><li><b>Bartonellosis - HIV infection:<\/b> (bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis) 500 mg ORALLY 4 times daily for at least 3 months<\/li><li><b>Chlamydial infection:<\/b> 800 mg ORALLY 4 times daily for 7 days (guideline dosing)  or 800 mg ORALLY 3 times daily for 7 days (manufacturer dosing)<\/li><li><b>Chlamydia trachomatis infection - Genitourinary chlamydia infection - Pregnancy:<\/b> 800 mg ORALLY 4 times daily for 7 days or 400 mg ORALLY 4 times daily for 14 days (guideline dosing)  OR 800 mg ORALLY 3 times daily for 7 days (manufacturer dosing)<\/li><li><b>Diphtheria, To antitoxin; Adjunct:<\/b> 400 mg ORALLY every 6 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Erythrasma:<\/b> 400 mg ORALLY every 6 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Female gonococcal pelvic inflammatory disease:<\/b> 400 mg ORALLY every 6 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Impetigo:<\/b> (Staphylococcus and Streptococcus species) 400 mg ORALLY 4 times daily for 7 days, depending on clinical response (guideline dosing)<\/li><li><b>Infection due to Entamoeba histolytica - Intestinal infectious disease:<\/b> 400 mg ORALLY four times daily for 10 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate), Caused by S. pyogenes or S. aureus:<\/b> 400 mg ORALLY every 6 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Legionnaires disease:<\/b> 1.6 to 4 g ORALLY daily in divided doses<\/li><li><b>Listeriosis:<\/b> 400 mg ORALLY every 6 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Lyme disease:<\/b> (alternative to first-line) 500 mg ORALLY four times daily for 14 to 21 days for early localized or early disseminated Lyme disease associated with erythema migrans, or borrelial lymphocytoma<\/li><li><b>Nongonococcal urethritis:<\/b> 800 mg ORALLY 4 times daily for 7 days (guideline dosing)  or 800 mg ORALLY 3 times daily for 7 days (manufacturer dosing)<\/li><li><b>Pertussis:<\/b> 40 to 50 mg\/kg\/day ORALLY in divided doses for 5 to 14 days; or 2 g\/day ORALLY in 4 divided doses for 14 days (guideline dosing)<\/li><li><b>Primary syphilis, In penicillin allergic patients:<\/b> 48 to 64 g ORALLY in divided doses over a period of 10 to 15 days<\/li><li><b>Respiratory tract infection:<\/b> 400 mg ORALLY every 6 hours or may give one-half the daily dose every 12 hours or one-third the daily dose every 8 hours (twice-daily dosing not recommended for doses above 1 g\/day); MAX 4 g\/day<\/li><li><b>Rheumatic fever, In penicillin allergic patients; Prophylaxis:<\/b> 400 mg ORALLY every 6 h; MAX 4 g\/day, depending on type and severity of infection for 10 days<\/li><\/ul>"},{"id":"211750-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>usual dosage 30 to 50 mg\/kg\/day orally in equally divided doses every 6 hours; dose may be doubled for more severe infections; may be given as one-half total daily dose every 12 hours or one-third total daily dose every 8 hours<\/li><li><b>Bartonellosis - HIV infection:<\/b> (cutaneous bacillary angiomatosis) 30 to 50 mg\/kg\/day (MAX 2 g\/day) ORALLY divided into 2 to 4 doses\/day for 3 months<\/li><li><b>Chlamydial infection:<\/b> (children less than 45 kg) 50 mg\/kg\/day ORALLY divided into 4 doses daily for 14 days<\/li><li><b>Chlamydia trachomatis infection - Genitourinary chlamydia infection - Pregnancy:<\/b> 800 mg ORALLY 3 times daily for 7 days<\/li><li><b>Diphtheria, To antitoxin; Adjunct:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses every 6 hours; dosage may be doubled for more severe infections, depending on type and severity of infection<\/li><li><b>Erythrasma:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses every 6 hours; dosage may be doubled for more severe infections<\/li><li><b>Female gonococcal pelvic inflammatory disease:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses every 6 hours; dosage may be doubled for more severe infections<\/li><li><b>Infection due to Entamoeba histolytica - Intestinal infectious disease:<\/b> 30 to 50 mg\/kg\/day ORALLY in divided doses for 10 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate), Caused by S. pyogenes or S. aureus:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses every 6 hours; dosage may be doubled for more severe infections<\/li><li><b>Listeriosis:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses every 6 hr; dosage may be doubled for more severe infections<\/li><li><b>Lyme disease:<\/b> (alternative to first-line) 12.5 mg\/kg ORALLY four times daily for 14 to 21 days for early localized or early disseminated Lyme disease associated with erythema migrans, or borrelial lymphocytoma; maximum daily dose, 2000 mg<\/li><li><b>Neonatal chlamydial conjunctivitis:<\/b> 50 mg\/kg\/day ORALLY in 4 divided doses for 14 days<\/li><li><b>Neonatal chlamydial pneumonia:<\/b> 50 mg\/kg\/day ORALLY divided into 4 doses daily for 14 days; dosage may be doubled for more severe infections<\/li><li><b>Pertussis:<\/b> 40 to 50 mg\/kg\/day ORALLY in divided doses for 5 to 14 days; 14 days preferred to avoid risk for relapse; MAX 2 g\/day; use not recommended if younger than 1 month (alternative is azithromycin)<\/li><li><b>Primary syphilis, In penicillin allergic patients:<\/b> 48 to 64 g ORALLY in divided doses over a period of 10 to 15 days<\/li><li><b>Respiratory tract infection:<\/b> 30 to 50 mg\/kg\/day ORALLY divided every 6 to 12 hours (2, 3, or 4 divided doses) for mild to moderate infections; may double the dose for severe infections<\/li><li><b>Respiratory tract infection:<\/b> community-acquired pneumonia; older than 3 months of age) 40 mg\/kg\/day ORALLY in 4 divided doses (guideline dosing)<\/li><li><b>Rheumatic fever, In penicillin allergic patients; Prophylaxis:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses every 6 h for 10 days; dosage may be doubled for more severe infections<\/li><\/ul>"},{"id":"211750-s-1-6","title":"Dose Adjustments","mono":"<b>hepatic impairment:<\/b> drug may accumulate in patients with severe liver disease; no specific dosing recommendations available"},{"id":"211750-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Chlamydial infection<\/li><li>Chlamydia trachomatis infection - Genitourinary chlamydia infection - Pregnancy<\/li><li>Diphtheria, To antitoxin; Adjunct<\/li><li>Erythrasma<\/li><li>Female gonococcal pelvic inflammatory disease<\/li><li>Impetigo<\/li><li>Infection due to Entamoeba histolytica - Intestinal infectious disease<\/li><li>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate), Caused by S. pyogenes or S. aureus<\/li><li>Legionnaires disease<\/li><li>Listeriosis<\/li><li>Neonatal chlamydial conjunctivitis<\/li><li>Neonatal chlamydial pneumonia<\/li><li>Nongonococcal urethritis<\/li><li>Pertussis<\/li><li>Primary syphilis, In penicillin allergic patients<\/li><li>Respiratory tract infection<\/li><li>Rheumatic fever, In penicillin allergic patients; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bartonellosis - HIV infection<\/li><li>Enteric campylobacteriosis<\/li><li>Lung disease, chronic - Ureaplasma urealyticum infection<\/li><li>Lyme disease<\/li><li>Otitis media<\/li><li>Premature rupture of membranes<\/li><\/ul>"}]},"3":{"id":"211750-s-3","title":"Contraindications\/Warnings","sub":[{"id":"211750-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant therapy with astemizole, cisapride, pimozide, or terfenadine<\/li><li>concomitant use with ergotamine or dihydroergotamine<\/li><li>hypersensitivity to erythromycin or any component of the product<\/li><\/ul>"},{"id":"211750-s-3-10","title":"Precautions","mono":"<ul><li>diarrhea (sometimes Clostridium difficile-associated), ranging in severity from mild diarrhea to fatal colitis, has been reported and may occur as late as 2 months or more after discontinuation; if occurs while still using, discontinuation may be necessary<\/li><li>elderly; potentially increased risk of erythromycin-associated hearing loss (especially with renal or hepatic dysfunction), QT-interval prolongation, and torsade de pointes<\/li><li>hepatic dysfunction (eg, increased liver enzymes, and hepatocellular and\/or cholestatic hepatitis, with or without jaundice) has been reported<\/li><li>hepatic function, impaired; risk of toxicity<\/li><li>infantile hypertrophic pyloric stenosis (IHPS) has been reported<\/li><li>myasthenia gravis, exacerbation, and new-onset myasthenic syndrome have been reported<\/li><li>pregnant women with early syphilis; oral erythromycin treatment may not reach the fetus adequately to prevent congenital syphilis<\/li><li>prolonged or repeated use; overgrowth of nonsusceptible bacteria or fungi (ie, superinfection) may occur; discontinuation recommended<\/li><li>QT prolongation has been reported, including cases of arrhythmia, torsade de pointes, and death; avoid use with known QT-interval prolongation, ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia, and concomitant use with Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics<\/li><\/ul>"},{"id":"211750-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Erythromycin: B (FDA)<\/li><li>Erythromycin: A (AUS)<\/li><\/ul>"},{"id":"211750-s-3-12","title":"Breast Feeding","mono":"<ul><li>Erythromycin: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Erythromycin: WHO: Compatible with breastfeeding.<\/li><li>Erythromycin: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"211750-s-4","title":"Drug Interactions","sub":[{"id":"211750-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Astemizole (probable)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (probable)<\/li><li>Colchicine (probable)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Fluconazole (theoretical)<\/li><li>Grepafloxacin (probable)<\/li><li>Levomethadyl (probable)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (probable)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"211750-s-4-14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Ajmaline (probable)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atorvastatin (probable)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Cerivastatin (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clindamycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (probable)<\/li><li>Disopyramide (probable)<\/li><li>Dofetilide (probable)<\/li><li>Dolasetron (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Encainide (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Eplerenone (probable)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Everolimus (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Gatifloxacin (probable)<\/li><li>Gemifloxacin (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (probable)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroquinidine (probable)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibrutinib (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Mefloquine (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pirmenol (probable)<\/li><li>Pitavastatin (probable)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Prajmaline (probable)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Quinine (probable)<\/li><li>Ranolazine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (established)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tadalafil (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Theophylline (established)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Troleandomycin (probable)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Verapamil (probable)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinblastine (probable)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (established)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"211750-s-4-15","title":"Moderate","mono":"<ul><li>Alfentanil (probable)<\/li><li>Alprazolam (probable)<\/li><li>Anisindione (probable)<\/li><li>Avanafil (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bromocriptine (probable)<\/li><li>Budesonide (probable)<\/li><li>Buspirone (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Diazepam (probable)<\/li><li>Dicumarol (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Midazolam (established)<\/li><li>Phenprocoumon (probable)<\/li><li>Roflumilast (established)<\/li><li>Salmeterol (established)<\/li><li>Sildenafil (probable)<\/li><li>Sirolimus (probable)<\/li><li>Tolterodine (probable)<\/li><li>Triazolam (probable)<\/li><li>Trimetrexate (probable)<\/li><li>Valproic Acid (probable)<\/li><li>Zafirlukast (probable)<\/li><\/ul>"}]},"5":{"id":"211750-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Abdominal pain, Diarrhea, Loss of appetite, Nausea, Vomiting<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Torsades de pointes, Ventricular tachycardia<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Acquired hypertrophic pyloric stenosis, infantile (5%), Pancreatitis, Pseudomembranous enterocolitis<\/li><li><b>Hepatic:<\/b>Decreased liver function<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Seizure<\/li><li><b>Renal:<\/b>Interstitial nephritis<\/li><\/ul>"},"6":{"id":"211750-s-6","title":"Drug Name Info","sub":{"0":{"id":"211750-s-6-17","title":"US Trade Names","mono":"<ul><li>E.E.S. 200<\/li><li>E.E.S. 400<\/li><li>E.E.S. Granules<\/li><li>Eryped<\/li><li>Eryped 200<\/li><li>Eryped 400<\/li><\/ul>"},"2":{"id":"211750-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Macrolide<\/li><\/ul>"},"3":{"id":"211750-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"211750-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"211750-s-7","title":"Mechanism Of Action","mono":"Erythromycin ethylsuccinate is a macrolide antibiotic derived from the strain of Saccharopolyspora erythraea. It inhibits protein synthesis by binding 50 S ribosomal subunits of susceptible microorganisms but does not affect nucleic acid synthesis.<br\/>"},"8":{"id":"211750-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"211750-s-8-23","title":"Absorption","mono":"Oral: readily and readily absorbed <br\/>"},"2":{"id":"211750-s-8-25","title":"Metabolism","mono":"Hepatic <br\/>"},"3":{"id":"211750-s-8-26","title":"Excretion","mono":"<ul><li>Fecal<\/li><li>Renal: less than 5% in active form<\/li><li>Dialyzable: no (hemodialysis); no (peritoneal dialysis)<\/li><\/ul>"}}},"9":{"id":"211750-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may be given without regard to meals<\/li><li>(suspension) shake well before measuring each dose<\/li><li>(suspension) after reconstitution, use within 35 days; no refrigeration required<\/li><\/ul>"},"10":{"id":"211750-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>hepatic function<\/li><li>hearing exam (hearing loss, especially with high doses and renal or hepatic insufficiency)<\/li><li>gonococcal acute pelvic inflammatory disease (penicillin sensitive patients): serologic test for syphilis before and 3 months after treatment<\/li><\/ul>"},"11":{"id":"211750-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Suspension: 200 MG\/5 ML, 400 MG\/5 ML<\/li><li>Oral Tablet: 400 MG<\/li><\/ul><\/li><li><b>E.E.S. 200<\/b><br\/>Oral Suspension: 200 MG\/5 ML<br\/><\/li><li><b>E.E.S. 400 Filmtab<\/b><br\/>Oral Tablet: 400 MG<br\/><\/li><li><b>E.E.S. 400<\/b><br\/>Oral Tablet: 400 MG<br\/><\/li><li><b>E.E.S. Granule<\/b><br\/>Oral Powder for Suspension: 200 MG\/5 ML<br\/><\/li><li><b>E.E.S. Granules<\/b><br\/>Oral Powder for Suspension: 200 MG\/5 ML<br\/><\/li><li><b>Eryped 200<\/b><br\/>Oral Powder for Suspension: 200 MG\/5 ML<br\/><\/li><li><b>Eryped 400<\/b><br\/>Oral Powder for Suspension: 400 MG\/5 ML<br\/><\/li><li><b>Eryped<\/b><br\/>Oral Powder for Suspension: 100 MG\/2.5 ML<br\/><\/li><\/ul>"},"12":{"id":"211750-s-12","title":"Toxicology","sub":[{"id":"211750-s-12-31","title":"Clinical Effects","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common. <br\/>"},{"id":"211750-s-12-32","title":"Treatment","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul>"},{"id":"211750-s-12-33","title":"Range of Toxicity","mono":"<b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity. <br\/>"}]},"13":{"id":"211750-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause dose-related nausea, vomiting, abdominal pain, diarrhea, and anorexia.<\/li><li>Advise parents or caregivers of infant patients to immediately report symptoms of infantile hypertrophic pyloric stenosis (IHPS), such as vomiting or irritability with feeding.<\/li><li>Instruct patient to immediately report watery and bloody stools (with or without stomach cramps and fever) that occurs during therapy; may also occur as late as 2 months after drug discontinuation.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}